Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;11(1):2275-2287.
doi: 10.1080/22221751.2022.2117098.

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2

Affiliations

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2

Bingjie Hu et al. Emerg Microbes Infect. 2022 Dec.

Abstract

SARS-CoV-2 B.1.1.529.1 (Omicron BA.1) emerged in November 2021 and quickly became the predominant circulating SARS-CoV-2 variant globally. Omicron BA.1 contains more than 30 mutations in the spike protein, which contribute to its altered virological features when compared to the ancestral SARS-CoV-2 or previous SARS-CoV-2 variants. Recent studies by us and others demonstrated that Omicron BA.1 is less dependent on transmembrane serine protease 2 (TMPRSS2), less efficient in spike cleavage, less fusogenic, and adopts an altered propensity to utilize the plasma membrane and endosomal pathways for virus entry. Ongoing studies suggest that these virological features of Omicron BA.1 are in part retained by the subsequent Omicron sublineages. However, the exact spike determinants that contribute to these altered features of Omicron remain incompletely understood. In this study, we investigated the spike determinants for the observed virological characteristics of Omicron. By screening for the individual changes on Omicron BA.1 and BA.2 spike, we identify that 69-70 deletion, E484A, and H655Y contribute to the reduced TMPRSS2 usage while 25-27 deletion, S375F, and T376A result in less efficient spike cleavage. Among the shared spike mutations of BA.1 and BA.2, S375F and H655Y reduce spike-mediated fusogenicity. Interestingly, the H655Y change consistently reduces serine protease usage while increases the use of endosomal proteases. In keeping with these findings, the H655Y substitution alone reduces plasma membrane entry and facilitates endosomal entry when compared to SARS-CoV-2 WT. Overall, our study identifies key changes in Omicron spike that contributes to our understanding on the virological determinant and pathogenicity of Omicron.

Keywords: Omicron BA.1 and BA.2; SARS-CoV-2; endosomal entry pathway; entry; fusogenicity; pathogenesis; spike protein cleavage.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Omicron BA.1 is less dependent on TMPRSS2-mediated plasma membrane entry pathway and is highly dependent on the endosomal entry pathway for virus entry. (A) Amino-acid sequence alignment of residues around the S1/S2 cleavage site of SARS-CoV-2 reference strain WIV04, HKU001a, Delta, Omicron BA.1, S1/S2-10Del, and S1/S2-AAAA. Amino acid positions are designated based on SARS-CoV-2 reference strain. (B–C) Calu3 and VeroE6 cells were challenged with SARS-CoV-2 WT, Delta, Omicron BA.1, or S1/S2-10Del. Cell lysates were harvested at 24 hpi for quantification of the subgenomic RNA of the envelope (sgE) gene (n = 6). (D–G) Calu3 and VeroE6 cells were pre-treated with indicated concentrations of camostat or E64D for 2 h followed by the authentic SARS-CoV-2 variants infection. The amount of viral subgenomic envelope RNA in harvested cell lysates at 24 hpi was determined by qRT-PCR (n = 4 for 50uM of camostat and E64D groups, n = 6 for the other groups). Error bars were calculated by using log-transformed data and represented mean ± SD from the indicated number of biological repeats. Statistical significances were determined with one way-ANOVA. Data were obtained from three independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant; WT, wildtype SARS-CoV-2.
Figure 2.
Figure 2.
Spike determinants for the reduced TMPRSS2 usage of Omicron BA.1 and BA.2. (A) Schematic of all amino acid mutation sites on Omicron BA.1 and BA.2 spike when compared to ancestral SARS-CoV-2 spike. (B) 293T cells were transfected with hACE2 or co-transfected with hACE2 and TMPRSS2, followed by transduction with pseudoviruses bearing the spike of SARS-CoV-2 D614G, Omicron BA.1, Omicron BA.2, S1/S2-10Del, S1/S2-AAAA and individual mutation at 24 h post-transfection. Pseudovirus entry was quantified by measuring the luciferase signal (n = 4). Fold changes in the luciferase signal were normalized to the mean luciferase readouts of cells with only hACE2 overexpression. Data represent mean ± SD from the indicated number of biological repeats. Statistical significance was determined with one way-ANOVA. Data were obtained from three independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant.
Figure 3.
Figure 3.
Spike determinants for the reduced spike cleavage of Omicron BA.1 and BA.2. (A) 293T cells were transfected with the indicated spike plasmids. Cell lysates were harvested at 24 h post-transfection for detection of SARS-CoV-2 spike cleavage using an anti-spike S2 antibody. Representative images of spike were shown with β-actin added as a sample processing control. Spike and β-actin were run on different gels and detected on different membranes. The experiment was repeated four times independently with similar results. (B) The cleavage ratio of different spikes from four times independent experiments was quantified by ImageJ. Data represent mean ± SD from the indicated number of biological repeats. Statistical significance was determined with one way-ANOVA. Data were obtained from four independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant.
Figure 4.
Figure 4.
Determinants for the reduced spike-mediated cell–cell fusion of Omicron BA.1 and BA.2. (A) Representative images of spike-mediated cell–cell fusion. 293T cells (effectors cells) were co-transfected with the indicated spike with GFP1-10, and were co-cultured with 293T cells co-transfected with human ACE2 (hACE2), TMPRSS2, and GFP11 (target cells). The co-cultured cells were fixed with 10% formalin and stained with DAPI. Representative images were from four independent experiments with similar results. (B) The fusion area was normalized with the SARS-CoV-2-D614G spike-mediated cell–cell fusion group by ImageJ. Data represent mean ± SD from the indicated number of biological repeats. Statistical significance was determined with one way-ANOVA. Data were obtained from four independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant.
Figure 5.
Figure 5.
Spike determinants for the altered entry mechanism of Omicron BA.1 and BA.2. A-D. 293T cells were transfected with hACE2 or co-transfected with hACE2 and TMPRSS13 (A), TMPRSS11D (B), Cathepsin L (C), or Cathepsin B (D), followed by transduction with pseudoviruses expressing the indicated spike at 24 h post-transfection. Pseudovirus entry was quantified by measuring the luciferase signal (n = 4). Fold changes in the luciferase signal were normalized to the mean luciferase readouts of cells with only hACE2 overexpression. Data represent mean ± SD from the indicated number of biological repeats. Statistical significance was determined with one way-ANOVA. Data were obtained from three independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant.
Figure 6.
Figure 6.
The H655Y substitution in Omicron BA.1 and BA.2 spike promotes endosomal entry. (A–B) VeroE6-TMPRSS2 cells were pre-treated with 1, 25, or 50μM camostat (A) or E64D (B) or DMSO (A–B) for 2 h followed by transduction with pseudoviruses expressing the indicated spike at 24 h post-transfection. Pseudovirus entry was quantified by measuring the luciferase signal (n = 5 for camostat treatment of Omicron BA.1, S1/S2-10Del, S1/S2-AAAA, and H655Y; n = 4 for the other groups). Data represent mean ± SD from the indicated number of biological repeats. Statistical significances were determined with one way-ANOVA. Data were obtained from three independent experiments. Each data point represents one biological repeat. * represented p < 0.05, ** represented p < 0.01, *** represented p < 0.001, and **** represented p < 0.0001. ns, not statistically significant.

References

    1. Chan JF, Yuan S, Kok KH, et al. . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514–523. - PMC - PubMed
    1. Zhou P, Yang XL, Wang XG, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273. - PMC - PubMed
    1. Chan JF, Kok KH, Zhu Z, et al. . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. - PMC - PubMed
    1. To KK, Sridhar S, Chiu KH, et al. . Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021 Dec;10(1):507–535. - PMC - PubMed
    1. Viana R, Moyo S, Amoako DG, et al. . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 Mar;603(7902):679–686. - PMC - PubMed

Substances

Supplementary concepts